"Hydrolases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any member of the class of enzymes that catalyze the cleavage of the substrate and the addition of water to the resulting molecules, e.g., ESTERASES, glycosidases (GLYCOSIDE HYDROLASES), lipases, NUCLEOTIDASES, peptidases (PEPTIDE HYDROLASES), and phosphatases (PHOSPHORIC MONOESTER HYDROLASES). EC 3.
| Descriptor ID |
D006867
|
| MeSH Number(s) |
D08.811.277
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydrolases".
Below are MeSH descriptors whose meaning is more specific than "Hydrolases".
This graph shows the total number of publications written about "Hydrolases" by people in this website by year, and whether "Hydrolases" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 1 | 1 | 2 |
| 2003 | 1 | 1 | 2 |
| 2004 | 3 | 0 | 3 |
| 2005 | 2 | 1 | 3 |
| 2006 | 0 | 1 | 1 |
| 2007 | 4 | 3 | 7 |
| 2008 | 1 | 2 | 3 |
| 2009 | 1 | 1 | 2 |
| 2010 | 5 | 2 | 7 |
| 2011 | 3 | 1 | 4 |
| 2012 | 7 | 0 | 7 |
| 2013 | 2 | 2 | 4 |
| 2014 | 4 | 1 | 5 |
| 2015 | 4 | 0 | 4 |
| 2016 | 1 | 4 | 5 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 2 | 2 |
| 2019 | 1 | 0 | 1 |
| 2021 | 3 | 2 | 5 |
| 2023 | 0 | 2 | 2 |
| 2024 | 2 | 2 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydrolases" by people in Profiles.
-
Citrulline and ADI-PEG20 reduce inflammation in a juvenile porcine model of acute endotoxemia. Front Immunol. 2024; 15:1400574.
-
Biochemical Characterization and Application of Zearalenone Lactone Hydrolase Fused with a Multifunctional Short Peptide. J Agric Food Chem. 2024 Aug 14; 72(32):18146-18154.
-
Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1. Hepatol Commun. 2024 May 01; 8(5).
-
Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Apr 01; 10(4):475-483.
-
Ultrasensitive one-pot detection of monkeypox virus with RPA and CRISPR in a sucrose-aided multiphase aqueous system. Microbiol Spectr. 2024 Jan 11; 12(1):e0226723.
-
Loss of the batten disease protein CLN3 leads to mis-trafficking of M6PR and defective autophagic-lysosomal reformation. Nat Commun. 2023 07 03; 14(1):3911.
-
Phase 1 trial of ADI-PEG 20 and liposomal doxorubicin in patients with metastatic solid tumors. Cancer Med. 2022 01; 11(2):340-347.
-
Enhancing the Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Signaling and Arginine Deprivation in Melanoma. Int J Mol Sci. 2021 Jul 16; 22(14).
-
Phase 1b study of pegylated arginine deiminase (ADI-PEG 20) plus Pembrolizumab in advanced solid cancers. Oncoimmunology. 2021; 10(1):1943253.
-
Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. Br J Cancer. 2021 04; 124(9):1533-1539.